However, paradoxically, only 20% of the patients with rheumatic mitral regurgitation were on ACE inhibitors or ARBs as noted in our study, which is the cornerstone of therapy in mitral regurgitation. This evidence concerns the gene ACE and mitral valve insufficiency.